NCT06361641 Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
| NCT ID | NCT06361641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Myeloproliferative Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-05-29 |
| Primary Completion | 2026-10-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-05-29 with a primary completion date of 2026-10-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms
Eligibility Criteria
Inclusion Criteria: * Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis) * Patient who has not received treatment specific to hemopathy at the time of sampling * Obtaining the signature of consent to participate in the study * Patient having consented to be included in the "Malignant Hemopathy" collection of Angers University Hospital and in FIMBANK database Exclusion Criteria: * Person not affiliated to a social security scheme or beneficiary of such a scheme * Patient with another hemopathy or another active cancer at the time of diagnosis * Minor patient at diagnosis (\< 18 years old) * Patient not capable or without agreement from the guardian or legal representative
Contact & Investigator
Agathe GOUBAND, PharmD
PRINCIPAL INVESTIGATOR
University Hospital
Frequently Asked Questions
Who can join the NCT06361641 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06361641 currently recruiting?
Yes, NCT06361641 is actively recruiting participants. Contact the research team at Agathe.Gouband@chu-angers.fr for enrollment information.
Where is the NCT06361641 trial being conducted?
This trial is being conducted at Angers, France, Cholet, France, Saumur, France.
Who is sponsoring the NCT06361641 clinical trial?
NCT06361641 is sponsored by University Hospital, Angers. The principal investigator is Agathe GOUBAND, PharmD at University Hospital. The trial plans to enroll 70 participants.